Trial Profile

A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms JKART-1
Sponsors Kite Pharma

16 Dec 2025 Actual primary completion date is 20 Nov 2025.
02 Oct 2025 Planned End Date changed from 1 May 2027 to 1 Jul 2027.
02 Oct 2025 Planned primary completion date changed from 1 May 2027 to 1 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com